There are currently no disease-modifying medications for the treatment of Huntington’s disease,  and current treatment is entirely dependent on symptomatic therapies. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss the current treatment landscape of Huntington’s disease and the limitations of current treatment options. Watch […]

Chorea is a common motor symptom of Huntington Disease (HD) which impacts motor function. Valbenazine, a potent and selective vesicular monoamine transporter 2 inhibitor, is being investigated for the treatment of chorea associated HD, and was approved for the treatment of tardive dyskinesia in the United States in 2017. Prof. Erin Furr-Stimming (McGovern Medical School, […]

Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. James Howard (The University of North Carolina at Chapel Hill, NC, USA) kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial open label extension study that evaluated the efficacy and […]

Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to […]

Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. Tuan Vu kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial that evaluated the efficacy and safety of ravulizumab, a potent terminal complement C5 inhibitor, in AChR Ab+ gMG. […]

Tolebrutinib is an oral, CNS-penetrant Bruton’s tyrosine kinase inhibitor with dual mechanism of action: peripheral B cell modulation and re-establishment of CNS microglial homeostasis. Dr Jiwon Oh (St. Michael’s Hospital, University of Toronto, Canada) joins us to discuss the phase 2b trial (NCT03889639), investigating safety and efficacy of tolebrutinib in patients with relapsing multiple sclerosis. […]

The efficacy and safety of fenfluramine, an anti-seizure medication, in patients with Lennox-Gastaut syndrome was assessed in phase 3 and open label extension studies (NCT03355209). Dr Kelly Knupp (Children’s Hospital Colorado, University of Colorado, CO, USA) discusses the findings of these studies and the impact its recent approval will have on clinical practice. The abstract […]

Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the potential use of bruton tyrosine kinase inhibitors (BTKis) in the treatment of multiple sclerosis. Prof. Cree discusses BTKis novel mechanism of action and the rationale behind the investigation of this new class of drugs. Question: What are the key clinical highlights in […]

Ublituximab is a novel glycoengineered monoclonal antibody treatment under investigation for relapsing remitting multiple sclerosis. Prof Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the phase 3 ULTIMATE I and II studies, and the positive results from the tertiary analysis of the data that investigated disability improvements in patients with relapsing multiple […]